Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Exercise shows minimal short-term benefit for osteoarthritis

17

Feb 2026

Exercise shows minimal short-term benefit for osteoarthritis

The effectiveness of exercise therapy to ease the symptoms of osteoarthritis is likely minimal, short lived, and probably no better than no treatment at all, suggests an overarching (umbrella) systematic review and pooled data analysis of the available evidence, published in the open access journal RMD Open.

Timing matters more than repetition in learning

17

Feb 2026

Timing matters more than repetition in learning

More than a century ago, Pavlov trained his dog to associate the sound of a bell with food. Ever since, scientists assumed the dog learned this through repetition: The more times the dog heard the bell and then got fed, the better it learned that the sound meant food would soon follow.

Short health ads reduce junk food cravings

17

Feb 2026

Short health ads reduce junk food cravings

A new Edith Cowan University (ECU) study has found advertisements that encourage healthy choices can reduce cravings and intentions to consume unhealthy foods, and in some cases a 15-second message may be more effective than traditional 30-second commercials.

Short-duration psychedelic therapy shows promise for major depression treatment

17

Feb 2026

Short-duration psychedelic therapy shows promise for major depression treatment

A phase IIa randomized trial found that intravenous dimethyltryptamine (DMT) with structured psychological support produced rapid reductions in depressive symptoms in adults with major depressive disorder. Improvements were statistically significant versus placebo at two weeks, with mostly mild-to-moderate adverse events and the need for larger confirmatory studies emphasized.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.